FSD Pharma Cash Flow Statement

Financials in millions CAD. Fiscal year is January - December.

Millions CAD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	2018 - 2017
Net Income	-9.85	-17.9	-23.61	-35.29	-31.8	-39.13	Upgrade
Depreciation & Amortization	1.5	2.51	4.53	4.05	3.9	1.94	Upgrade
Share-Based Compensation	0.69	3.84	1.53	7.44	8.05	12.08	Upgrade
Other Operating Activities	-0.38	0.73	-10.79	3.05	0.72	11.39	Upgrade
Operating Cash Flow	-8.05	-10.83	-28.33	-20.75	-19.13	-13.71	Upgrade
Capital Expenditures	0	0	-0.36	-0.5	0	-0.29	Upgrade
Acquisitions	-	0.03	0	0.77	0	0	Upgrade
Change in Investments	-0.32	-0.3	-0.24	0	6.48	0.46	Upgrade
Other Investing Activities	0.03	-	12.73	-	0.04	-0.4	Upgrade
Investing Cash Flow	-0.29	-0.27	12.12	0.27	6.51	-0.23	Upgrade
Share Issuance / Repurchase	0.31	-2.94	-1.93	38.34	25.16	4.05	Upgrade
Debt Issued / Paid	0.14	-0.19	-0.14	-0.13	-0.99	-0.04	Upgrade
Financing Cash Flow	0.45	-3.13	-2.07	38.21	24.17	4.01	Upgrade
Net Cash Flow	-7.89	-14.22	-18.28	17.73	11.56	-9.93	Upgrade
Free Cash Flow	-8.05	-10.83	-28.7	-21.25	-19.13	-14.01	Upgrade
Free Cash Flow Per Share	-0.20	-0.27	-0.74	-0.61	-1.59	-1.99	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from audited reports submitted to the Securities and Exchange Commission (SEC).